Press Releases

MaaT Pharma Awarded France Relance Government Grant to Accelerate Development in Immuno-Oncology and Support Manufacturing of Next Generation Microbiome Therapies

MaaT Pharma awarded non-dilutive funding of EURO 1.9 million for its “MEPA” project through the…

MaaT PharmaJuly 20, 2021

Press Releases

MaaT Pharma, lauréat de France Relance, accélère son développement dans l’immuno-oncologie et la production de médicaments microbiote de nouvelle génération

MaaT Pharma a obtenu un financement non-dilutif de 1,9 million d’euros pour son projet MEPA,…

MaaT PharmaJuly 20, 2021

Press Releases

MaaT Pharma Announces DSMB Approval to Proceed to Cohort 4 out of 5 in Phase 1b CIMON Trial Testing Capsule Formulation of Microbiome Ecosystem Therapy

Independent Data Safety and Monitoring Board (DSMB) recommends continuing study as planned and initiating dosing…

MaaT PharmaJune 28, 2021

Videos

IABS Bioaster – FMT WEBINAR

Watch the replay of the presentation by Our CEO Herve Affagard, MBA, Eng., during the…

MaaT PharmaJune 2, 2021

Press ReleasesScientific Publications

MaaT Pharma Announces Publication of Results from Completed Phase 1/2 ODYSSEE Clinical Trial in Nature Communications

The trial of the autologous microbial therapy, MaaT011, met its primary endpoints through demonstration of…

MaaT PharmaMay 25, 2021

Videos

EY : Prix de l’Entrepreneur de l’Année

Découvrez ci-dessous l'intervention de notre CEO Herve Affagard, MBA, Eng. pour le Prix de l'Entrepreneur de…

MaaT PharmaMay 5, 2021

Videos

Hybridays 2021: Savita BERNAL, Chief Business Officer at MaatPharma

Our Chief Business Officer Savita Bernal attended HYBRID 2021, on March 16th, an event focused this…

MaaT PharmaApril 28, 2021

Press Releases

Lancement de l’Alliance Promotion Microbiote

Communiqué de presse Lancement de l’Alliance Promotion Microbiote Le 29 mars 2021 – L’Alliance Promotion…

MaaT PharmaMarch 29, 2021

Press Releases

MaaT Pharma annonce des premiers résultats positifs dans l’essai clinique de phase 2 HERACLES avec MaaT013 chez les patients atteints d’une maladie du greffon contre l’hôte aiguë (aGvHD)

L'étude atteint ses objectifs clés, principaux et secondaires, avec un impact clinique positif et une…

MaaT PharmaMarch 17, 2021

Press Releases

MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease

Study meets primary and key secondary objectives with positive impact and favorable overall safety profile…

MaaT PharmaMarch 17, 2021